{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:19:02Z","timestamp":1791497942491,"version":"4.3.4"},"reference-count":112,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background and objective<\/jats:title>\n<jats:p>The prognostic value of age and other non-hematological factors in predicting outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) undergoing antileukemic therapy is not well understood. We performed a systematic review to determine the association between these factors and mortality and health-related quality of life or fatigue among these patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We searched Medline and Embase through October 2021 for studies in which researchers quantified the relationship between age, comorbidities, frailty, performance status, or functional status; and mortality and health-related quality of life or fatigue in older patients with AML receiving antileukemic therapy. We assessed the risk of bias of the included studies using the Quality in Prognostic Studies tool, conducted random-effects meta-analyses, and assessed the quality of the evidence using the Grading of Recommendations, Assessment, Development and Evaluation approach.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>We included 90 studies. Meta-analysis showed that age (per 5-year increase, HR 1.16 95% CI 1.11\u20131.21, high-quality evidence), comorbidities (Hematopoietic Cell Transplantation-specific Comorbidity Index: 3+ VS less than 3, HR 1.60 95% CI 1.31\u20131.95, high-quality evidence), and performance status (Eastern Cooperative Oncology Group\/ World Health Organization (ECOG\/WHO): 2+ VS less than 2, HR 1.63 95% CI 1.43\u20131.86, high-quality evidence; ECOG\/WHO: 3+ VS less than 3, HR 2.00 95% CI 1.52\u20132.63, moderate-quality evidence) were associated with long-term mortality. These studies provided inconsistent and non-informative results on short-term mortality (within 90 days) and quality of life.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>High-quality or moderate-quality evidence support that age, comorbidities, performance status predicts the long-term prognosis of older patients with AML undergoing antileukemic treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0278578","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T18:26:01Z","timestamp":1670264761000},"page":"e0278578","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-5144","authenticated-orcid":true,"given":"Qiukui","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Foroutan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Ah","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahira","family":"Devji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Kenji","family":"Nampo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipto","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabbir M. H.","family":"Alibhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon H.","family":"Guyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Brignardello-Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"pone.0278578.ref001","unstructured":"Bethesda M. SEER Cancer Statistics Review, 1975\u20132015, National Cancer Institute based on November 2017 SEER data submission, posted to the SEER web site https:\/\/seer.cancer.gov\/csr\/1975_2015\/2018"},{"issue":"18","key":"pone.0278578.ref002","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"G Juliusson","year":"2009","journal-title":"Blood"},{"issue":"10147","key":"pone.0278578.ref003","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"NJ Short","year":"2018","journal-title":"Lancet"},{"issue":"15","key":"pone.0278578.ref004","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades","volume":"119","author":"MS Thein","year":"2013","journal-title":"Cancer"},{"issue":"8","key":"pone.0278578.ref005","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14656566.2018.1465562","article-title":"Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia","volume":"19","author":"LC Michaelis","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"pone.0278578.ref006","article-title":"Geriatric Assessment in Older Patients with Acute Myeloid Leukemia","volume":"10","author":"KP Loh","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"6","key":"pone.0278578.ref007","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3322\/canjclin.51.6.329","article-title":"Comorbidity considerations in geriatric oncology research","volume":"51","author":"JW Yates","year":"2001","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"pone.0278578.ref008","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jgo.2019.04.009","article-title":"Age-related cytokine effects on cancer-related fatigue and quality of life in acute myeloid leukemia","volume":"11","author":"SMH Alibhai","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"10","key":"pone.0278578.ref009","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/s41375-019-0449-1","article-title":"Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy","volume":"33","author":"A El-Jawahri","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"pone.0278578.ref010","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3324\/haematol.2010.036715","article-title":"Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians","volume":"96","author":"EN Oliva","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"pone.0278578.ref011","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.3324\/haematol.2021.279174","article-title":"Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial","volume":"106","author":"GJ Roboz","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"pone.0278578.ref012","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bmt.2017.182","article-title":"Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome","volume":"52","author":"D Modi","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"pone.0278578.ref013","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/leu.2016.54","article-title":"Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia","volume":"30","author":"T Buchner","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"pone.0278578.ref014","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality","volume":"3","author":"ML Sorror","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"pone.0278578.ref015","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"BC Medeiros","year":"2015","journal-title":"Ann Hematol"},{"issue":"21","key":"pone.0278578.ref016","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"HD Klepin","year":"2013","journal-title":"Blood"},{"key":"pone.0278578.ref017","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2018.05.026","article-title":"Myelodysplastic syndromes and acute myeloid leukemias in the elderly","volume":"58","author":"BU Mueller","year":"2018","journal-title":"Eur J Intern Med"},{"issue":"15","key":"pone.0278578.ref018","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"MA Sekeres","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"pone.0278578.ref019","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"JA Hayden","year":"2013","journal-title":"Ann Intern Med"},{"issue":"4","key":"pone.0278578.ref020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"S Balduzzi","year":"2019","journal-title":"Evidence-based mental health"},{"key":"pone.0278578.ref021","doi-asserted-by":"crossref","first-page":"h870","DOI":"10.1136\/bmj.h870","article-title":"Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients","volume":"350","author":"A Iorio","year":"2015","journal-title":"BMJ"},{"issue":"35","key":"pone.0278578.ref022","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2013.49.0771","article-title":"Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)","volume":"31","author":"S Amadori","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"pone.0278578.ref023","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1182\/blood-2001-12-0354","article-title":"Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study","volume":"100","author":"JE Anderson","year":"2002","journal-title":"Blood"},{"issue":"8","key":"pone.0278578.ref024","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1054\/bjoc.1999.1123","article-title":"Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden","volume":"82","author":"M Astrom","year":"2000","journal-title":"Br J Cancer"},{"issue":"5","key":"pone.0278578.ref025","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/leu.2011.9","article-title":"Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720","volume":"25","author":"MR Baer","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"pone.0278578.ref026","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/cncr.22976","article-title":"Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia","volume":"110","author":"R Baz","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"pone.0278578.ref027","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hon.2663","article-title":"Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy","volume":"37","author":"M Bocchia","year":"2019","journal-title":"Hematol Oncol"},{"issue":"16","key":"pone.0278578.ref028","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1002\/cncr.30704","article-title":"Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach","volume":"123","author":"PC Boddu","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"pone.0278578.ref029","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1002\/ajh.23848","article-title":"Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network","volume":"89","author":"P Bories","year":"2014","journal-title":"Am J Hematol"},{"issue":"8","key":"pone.0278578.ref030","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ajh.23462","article-title":"Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia","volume":"88","author":"AM Brunner","year":"2013","journal-title":"Am J Hematol"},{"issue":"8","key":"pone.0278578.ref031","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.3109\/10428194.2014.985672","article-title":"Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study","volume":"56","author":"BK Budziszewska","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"pone.0278578.ref032","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2009.07604.x","article-title":"The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial","volume":"145","author":"AK Burnett","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"pone.0278578.ref033","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2005-11-4354","article-title":"Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461","volume":"108","author":"Cancer, Leukemia Group B","year":"2006","journal-title":"Blood"},{"issue":"7\u20138","key":"pone.0278578.ref034","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000487804","article-title":"Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia","volume":"41","author":"C Chen","year":"2018","journal-title":"Oncol Res Treat"},{"issue":"30","key":"pone.0278578.ref035","doi-asserted-by":"crossref","first-page":"e4182","DOI":"10.1097\/MD.0000000000004182","article-title":"The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy","volume":"95","author":"Y Chen","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"pone.0278578.ref036","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.clml.2018.02.018","article-title":"Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease","volume":"18","author":"E Collinge","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"pone.0278578.ref037","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00277-012-1478-2","article-title":"Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients","volume":"91","author":"M Colovic","year":"2012","journal-title":"Ann Hematol"},{"issue":"20","key":"pone.0278578.ref038","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2010-04-277269","article-title":"Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999","volume":"116","author":"LD Cripe","year":"2010","journal-title":"Blood"},{"issue":"3","key":"pone.0278578.ref039","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/10245332.2001.11746568","article-title":"Acute Myelogenous Leukaemia in Patients 60 Years and Older: A Retrospective Analysis from St Bartholomew\u2019s Hospital 1969\u20131999","volume":"6","author":"CD Dalley","year":"2001","journal-title":"Hematol"},{"key":"pone.0278578.ref040","article-title":"Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP)","volume":"20","author":"M Delia","year":"2015","journal-title":"Leukemia Research"},{"issue":"2","key":"pone.0278578.ref041","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1179\/102453312X13221316477651","article-title":"Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia","volume":"17","author":"I Djunic","year":"2012","journal-title":"Hematol"},{"issue":"3","key":"pone.0278578.ref042","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"H Dombret","year":"2015","journal-title":"Blood"},{"issue":"5","key":"pone.0278578.ref043","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/10428194.2017.1365854","article-title":"Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC\/LRF score: results from the expanded international E-ALMA series (E-ALMA+)","volume":"59","author":"J Falantes","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"pone.0278578.ref044","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clml.2015.02.022","article-title":"Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia","volume":"15","author":"J Fattoum","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"pone.0278578.ref045","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.leukres.2018.11.015","article-title":"Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience","volume":"76","author":"C Fili","year":"2019","journal-title":"Leuk Res"},{"issue":"10","key":"pone.0278578.ref046","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B","volume":"108","author":"S Frohling","year":"2006","journal-title":"Blood"},{"issue":"8","key":"pone.0278578.ref047","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/imj.12169","article-title":"Acute myeloid leukaemia in Western Australia 1991\u20132005: A retrospective population-based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome","volume":"43","author":"S Gangatharan","year":"2013","journal-title":"Internal Medicine Journal"},{"issue":"3","key":"pone.0278578.ref048","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO.2011.40.3642","article-title":"Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older","volume":"31","author":"C Gardin","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"pone.0278578.ref049","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1182\/blood-2007-02-069666","article-title":"Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial","volume":"109","author":"C Gardin","year":"2007","journal-title":"Blood"},{"issue":"7","key":"pone.0278578.ref050","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1016\/j.clml.2018.05.005","article-title":"Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single-Institution Experience","volume":"18","author":"B Gbadamosi","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"pone.0278578.ref051","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V98.5.1302","article-title":"Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"AH Goldstone","year":"2001","journal-title":"Blood"},{"issue":"3","key":"pone.0278578.ref052","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3233\/CBM-181602","article-title":"CD45 correlates with adverse risk stratification, decreased treatment response and unfavorable survival profiles in elderly acute myeloid leukemia patients","volume":"23","author":"L Guo","year":"2018","journal-title":"Cancer Biomark"},{"issue":"10","key":"pone.0278578.ref053","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/cncr.21006","article-title":"Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy","volume":"103","author":"V Gupta","year":"2005","journal-title":"Cancer"},{"issue":"4","key":"pone.0278578.ref054","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040570","article-title":"Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience","volume":"11","author":"M Heiblig","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0278578.ref055","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1186\/s12885-018-5160-5","article-title":"Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia","volume":"18","author":"J Huang","year":"2018","journal-title":"BMC Cancer"},{"issue":"3","key":"pone.0278578.ref056","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"E Hulegardh","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"pone.0278578.ref057","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00432-015-2045-8","article-title":"Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)","volume":"142","author":"C Kahl","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"pone.0278578.ref058","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"H Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"pone.0278578.ref059","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajh.23337","article-title":"Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients","volume":"88","author":"I Kim","year":"2013","journal-title":"Am J Hematol"},{"issue":"9757","key":"pone.0278578.ref060","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/S0140-6736(10)62105-8","article-title":"Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes","volume":"376","author":"U Krug","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"pone.0278578.ref061","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2006-04-014357","article-title":"A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia","volume":"109","author":"JE Lancet","year":"2007","journal-title":"Blood"},{"issue":"12","key":"pone.0278578.ref062","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3324\/haematol.13309","article-title":"Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia","volume":"93","author":"JV Malfuson","year":"2008","journal-title":"Haematologica"},{"issue":"11","key":"pone.0278578.ref063","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00277-017-3104-9","article-title":"Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy","volume":"96","author":"SB Oh","year":"2017","journal-title":"Ann Hematol"},{"issue":"8","key":"pone.0278578.ref064","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.leukres.2013.02.018","article-title":"Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: a multicenter retrospective study","volume":"37","author":"N Okuyama","year":"2013","journal-title":"Leukemia Research"},{"issue":"12","key":"pone.0278578.ref065","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"B Oran","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"pone.0278578.ref066","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/leu.2014.234","article-title":"Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study","volume":"29","author":"LS Ostgard","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"pone.0278578.ref067","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2014.58.0571","article-title":"Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute\/Medical Research Council report","volume":"33","author":"F Ostronoff","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"pone.0278578.ref068","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2009.23.2652","article-title":"Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study","volume":"28","author":"C Pautas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"pone.0278578.ref069","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1200\/JCO.2009.26.4648","article-title":"Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS","volume":"28","author":"A Pigneux","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"pone.0278578.ref070","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3324\/haematol.2018.191536","article-title":"Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older","volume":"103","author":"VV Prassek","year":"2018","journal-title":"Haematologica"},{"issue":"28","key":"pone.0278578.ref071","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1200\/JCO.2008.21.0674","article-title":"Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup","volume":"27","author":"T Prebet","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"pone.0278578.ref072","first-page":"296","article-title":"Survival of elderly patients with acute myeloid leukemia","volume":"89","author":"A Pulsoni","year":"2004","journal-title":"Haematologica"},{"issue":"3","key":"pone.0278578.ref073","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.leukres.2014.12.013","article-title":"Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction","volume":"39","author":"F Ramos","year":"2015","journal-title":"Leukemia Research"},{"issue":"6","key":"pone.0278578.ref074","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2010-01-267302","article-title":"A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial","volume":"116","author":"C Rollig","year":"2010","journal-title":"Blood"},{"issue":"11","key":"pone.0278578.ref075","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/sj.leu.2403528","article-title":"Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia","volume":"18","author":"RF Schlenk","year":"2004","journal-title":"Leukemia"},{"issue":"9","key":"pone.0278578.ref076","first-page":"1082","article-title":"The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups","volume":"89","author":"C Schoch","year":"2004","journal-title":"Haematologica"},{"issue":"1","key":"pone.0278578.ref077","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2008-05-157065","article-title":"Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients","volume":"113","author":"MA Sekeres","year":"2009","journal-title":"Blood"},{"issue":"1","key":"pone.0278578.ref078","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000437131","article-title":"High-Intensity Induction Chemotherapy Is Feasible for Elderly Patients with Acute Myeloid Leukemia","volume":"135","author":"A Shacham-Abulafia","year":"2016","journal-title":"Acta Haematologica"},{"issue":"9","key":"pone.0278578.ref079","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.leukres.2013.05.013","article-title":"Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes","volume":"37","author":"AE Sherman","year":"2013","journal-title":"Leukemia Research"},{"issue":"1","key":"pone.0278578.ref080","first-page":"8","article-title":"Preliminary study of HCT-CI score system for prognosis prediction in elderly patients with acute myeloid leukemia after chemotherapy","volume":"34","author":"J Shi","year":"2013","journal-title":"Chung Hua Hsueh Yeh Hsueh Tsa Chi"},{"issue":"3","key":"pone.0278578.ref081","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.clml.2015.11.016","article-title":"Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients","volume":"16","author":"K Takahashi","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"pone.0278578.ref082","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2013-12-546283","article-title":"Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients","volume":"123","author":"M Tassara","year":"2014","journal-title":"Blood"},{"issue":"1","key":"pone.0278578.ref083","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jgo.2015.10.182","article-title":"Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML)","volume":"7","author":"B Tawfik","year":"2016","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"pone.0278578.ref084","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ajh.23654","article-title":"Azacitidine in untreated acute myeloid leukemia: a report on 149 patients","volume":"89","author":"S Thepot","year":"2014","journal-title":"Am J Hematol"},{"key":"pone.0278578.ref085","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.leukres.2016.06.001","article-title":"Do quality of life, physical function, or the Wheatley index at diagnosis predict 1-year mortality with intensive chemotherapy in older acute myeloid leukemia patients?","volume":"47","author":"N Timilshina","year":"2016","journal-title":"Leuk Res"},{"issue":"3","key":"pone.0278578.ref086","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1158\/1078-0432.CCR-07-2063","article-title":"The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients","volume":"14","author":"AM Tsimberidou","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"pone.0278578.ref087","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.leukres.2018.10.011","article-title":"Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience","volume":"75","author":"P Vachhani","year":"2018","journal-title":"Leuk Res"},{"issue":"8","key":"pone.0278578.ref088","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.leukres.2013.03.022","article-title":"Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts","volume":"37","author":"LH van der Helm","year":"2013","journal-title":"Leukemia Research"},{"issue":"2","key":"pone.0278578.ref089","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cncr.20353","article-title":"The benefit of induction chemotherapy in patients age > or = 75 years","volume":"101","author":"N Vey","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"pone.0278578.ref090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2141.2001.03043.x","article-title":"Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia","volume":"115","author":"A Wahlin","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"pone.0278578.ref091","first-page":"692","article-title":"Clinical Characteristics and Prognosis of 84 Elderly Patients with Acute Myeloid Leukemia","volume":"27","author":"W Wan","year":"2019","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"3","key":"pone.0278578.ref092","first-page":"194","article-title":"Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen","volume":"37","author":"J Wang","year":"2016","journal-title":"Chung Hua Hsueh Yeh Hsueh Tsa Chi"},{"issue":"5","key":"pone.0278578.ref093","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2141.2009.07663.x","article-title":"Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials","volume":"145","author":"K Wheatley","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"pone.0278578.ref094","first-page":"396","article-title":"Easily manageable prognostic factors in 152 Chinese elderly acute myeloid leukemia patients: a single-center retrospective study","volume":"28","author":"J Xu","year":"2014","journal-title":"J"},{"issue":"1","key":"pone.0278578.ref095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0145-2126(00)00089-8","article-title":"De novo acute myeloid leukemia in the elderly; a consistent fraction of long-term survivors by standard-dose chemotherapy","volume":"25","author":"S Yoshida","year":"2001","journal-title":"Leukemia Research"},{"issue":"2","key":"pone.0278578.ref096","first-page":"387","article-title":"Treatment Selection of Elderly Acute Myeloid Leukemia Patients Guided by HCT-CI Score","volume":"25","author":"W Zhang","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"1","key":"pone.0278578.ref097","first-page":"3","article-title":"Prognostic analysis of non-cytogenetic factors in elderly adults with acute myeloid leukemia","volume":"34","author":"BB Zhao","year":"2013","journal-title":"Chung Hua Hsueh Yeh Hsueh Tsa Chi"},{"issue":"4","key":"pone.0278578.ref098","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jgo.2015.04.002","article-title":"Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age","volume":"6","author":"SM Alibhai","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"7","key":"pone.0278578.ref099","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.18632\/aging.102973","article-title":"Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML","volume":"12","author":"M Hong","year":"2020","journal-title":"Aging"},{"issue":"6","key":"pone.0278578.ref100","first-page":"3473","article-title":"A retrospective study of the association of low 25(OH) vitamin D3 levels with poor outcomes in elderly patients with de novo acute myeloid leukaemia","volume":"36","author":"B Hu","year":"2020","journal-title":"Acta Medica Mediterranea"},{"issue":"1","key":"pone.0278578.ref101","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/bjh.16410","article-title":"Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged > = 60 years","volume":"189","author":"A Osterroos","year":"2020","journal-title":"Br J Haematol"},{"issue":"10","key":"pone.0278578.ref102","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1007\/s00277-020-04217-w","article-title":"Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience","volume":"99","author":"S Pepe","year":"2020","journal-title":"Ann Hematol"},{"issue":"24","key":"pone.0278578.ref103","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"AH Wei","year":"2020","journal-title":"Blood"},{"issue":"7","key":"pone.0278578.ref104","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.26190","article-title":"Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice","volume":"96","author":"A Apel","year":"2021","journal-title":"Am J Hematol"},{"issue":"16","key":"pone.0278578.ref105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/cancers13164189","article-title":"Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG)","volume":"13","author":"BK Budziszewska","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"pone.0278578.ref106","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/cancers13092156","article-title":"The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively","volume":"13","author":"M Heiblig","year":"2021","journal-title":"Cancers"},{"key":"pone.0278578.ref107","first-page":"11","article-title":"Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia","volume":"11","author":"JD Peipert","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"pone.0278578.ref108","first-page":"27","article-title":"Treatment patterns and a prognostic scoring system for elderly acute myeloid leukemia patients: a retrospective multicenter cohort study in China","volume":"27","author":"C Zhang","year":"2021","journal-title":"Cancer Biol"},{"issue":"10","key":"pone.0278578.ref109","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","article-title":"Clinical outcomes of older patients with AML receiving hypomethylating agents: A large population-based study in the United States","volume":"4","author":"AM Zeidan","year":"2020","journal-title":"Blood Advances"},{"issue":"2","key":"pone.0278578.ref110","doi-asserted-by":"crossref","first-page":"e12810","DOI":"10.1111\/ecc.12810","article-title":"Frailty in patients with acute myeloid leukaemia, conceptual misapprehension of chronological age","volume":"27","author":"EG Umit","year":"2018","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"4","key":"pone.0278578.ref111","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.beha.2017.09.008","article-title":"Do cytogenetics affect the post-remission strategy for older patients with AML in CR1?","volume":"30","author":"JM Foran","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"pone.0278578.ref112","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/CMAR.S242479","article-title":"Genetic Characterization and Risk Stratification of Acute Myeloid Leukemia","volume":"12","author":"F Pourrajab","year":"2020","journal-title":"Cancer Manag Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T18:27:02Z","timestamp":1670264822000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278578"}},"subtitle":[],"editor":[{"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":112,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0278578","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]}}}